CJ-42794 manufacturers
- CJ-42794
-
- $32.00
-
2026-07-14
- CAS:847728-01-2
- Purity: 99.92%
- Supply Ability: 10g
|
| | CJ-42794 Basic information |
| Product Name: | CJ-42794 | | Synonyms: | 4-[(1S)-1-[[5-chloro-2-(4-fluorophenoxy)benzoyl]amino]ethyl]Benzoic acid;(S)-4-(1-(5-chloro-2-(4-fluorophenoxy)benzaMido)ethyl)benzoic acid;CJ-042794;4-((S)-1-(2-(4-fluorophenoxy)-5-chlorobenzamido)ethyl)benzoic acid;CJ-42794;CJ-042794;CJ42794;CJ 42794;Benzoic acid, 4-[(1S)-1-[[5-chloro-2-(4-fluorophenoxy)benzoyl]amino]ethyl]-;RQ-00015986 | | CAS: | 847728-01-2 | | MF: | C22H17ClFNO4 | | MW: | 413.83 | | EINECS: | | | Product Categories: | | | Mol File: | 847728-01-2.mol |  |
| | CJ-42794 Chemical Properties |
| Boiling point | 572.7±50.0 °C(Predicted) | | density | 1.347±0.06 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | insoluble in H2O; ≥11.7 mg/mL in DMSO; ≥54.6 mg/mL in EtOH | | form | A crystalline solid | | pka | 4.21±0.10(Predicted) | | color | White to off-white |
| | CJ-42794 Usage And Synthesis |
| Uses | CJ-42794 (CJ-042794) is a potent, orally active, selective prostaglandin E receptor 4 (EP4) antagonist with an IC50 value of 10 nM, which is 200-fold more selective than EP1, EP2 and EP3. CJ-42794 can be used in research of gastric ulcers[1][2]. | | Definition | ChEBI: Benzoic acid, 4-[(1s)-1-[[5-chloro-2-(4-fluorophenoxy)benzoyl]amino]ethyl]- is an aromatic ether. | | Biological Activity | ki: 3.16 nm: antagonizes e prostanoid receptor 4 (ep4).ki: 631 nm: antagonizes ep2.cj-42794, as a selective antagonist of ep4, less binds to ep2 and does not have binding affinity for ep1 or ep3. it displays minimal effect on numerous other receptors, channels, or enzymes. cj-42794 delays the healing of gastric ulcers, inhibiting the upregulation of vegf expression and angiogenesis. ep4, activated by prostaglandin e2 (pge2), is a g-protein-coupled receptor, which plays vital roles in bone formation and resorption, cancer, and atherosclerosis via elevating the second messenger cyclic amp (camp). | | in vitro | cj-42794 exhibited remarkable binding activity to ep4 and suppressed pge2-triggered elevations of intracellular camp levels in a concentration-dependent fashion in hek293 cells overexpressing human ep4. moreover, cj-42794, concentration-dependently, reversed the inhibitory effects of pge2 on lipopolysaccharide-evoked tumor necrosis factor α production, which suggested that cj-42794 had excellent pharmacological properties used for exploring the physiological role of ep4 [1]. | | in vivo | male sprague-dawley rats and c57bl/6 mice were given subcutaneously 3 and 10 mg/kg for rats, 10 mg/kg for mice once daily for 7 or 14 days. compared to the controls, cj-42794, in a dose-dependent manner, impaired and delayed the gastric ulcer healing in rats and mice. cj-42794 markedly dampened the increase of vegf expression in ulcerated mucosa of the mouse stomach and the primary gastric fibroblasts of rat [2]. | | IC 50 | EP: 10 nM (EC50) | | references | [1]. murase, a., taniguchi, y., tonai-kachi, h., nakao, k., & takada, j. in vitro pharmacological characterization of cj-042794, a novel, potent, and selective prostaglandin ep4 receptor antagonist. life sciences. 2008; 82(3-4): 226-232.
[2]. hatazawa, r., tanaka, a., tanigami, m., amagase, k., kato, s., ashida, y., & takeuchi, k. cyclooxygenase-2/prostaglandin e2 accelerates the healing of gastric ulcers via ep4 receptors. ajp: gastrointestinal and liver physiology. 2007; 293(4): g788-g797. |
| | CJ-42794 Preparation Products And Raw materials |
|